You can buy or sell RARE and other stocks, options, ETFs, and crypto commission-free!
Ultragenyx Pharmaceutical Inc. Common Stock, also called Ultragenyx Pharmaceutical, is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Read More Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
52 Week High
52 Week Low
Stock Price, News, & Analysis for Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is developing various biologics product candidates, including Burosumab, a human monoclonal antibody that ...
Simply Wall StMar 2
Is Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) A Financially Strong Company?
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Ultragenyx Pharmaceutical Inc.
Expected May 6, After Hours